Publications

Liprotamase

  • Hetrick EM, Sperry DC, Nguyen HK, Strege MA. Characterization of a novel cross-linked lipase: impact of cross-linking on solubility and release from drug product. Mol Pharm. 2014 Apr 7;11(4):1189-200. doi: 10.1021/mp4006529.
  • Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H; Liprotamase 767 Study Group. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):248-57. doi: 10.1097/MPG.0b013e31823315d1.
  • Borowitz D, Stevens C, Brettman LR, Campion M, Chatfield B, Cipolli M; Liprotamase 726 Study Group. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros. 2011 Dec;10(6):443-52. doi: 10.1016/j.jcf.2011.07.001. Epub 2011 Aug 9.
  • Borowitz D, Konstan MW, O’Rourke A, Cohen M, Hendeles L, Murray FT.Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther. 2007 Jan;12(1):47-52. doi: 10.5863/1551-6776-12.1.47.
  • Borowitz D, Goss CH, Limauro S, Konstan MW, Blake K, Casey S, Quittner AL, Murray FT. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr. 2006 Nov;149(5):658-662.
  • Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O’Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR Jr, Dunitz J, Murray FT. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas. 2006 Apr;32(3):258-63.

Blisibimod

  • Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144.
  • Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, Ginzler EM, Cooke B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Tsuji W, Zack DJ. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20;17:215. doi: 10.1186/s13075-015-0741-z. Petri M, Martin RS, Hislop C, Scheinberg MA, Furie RA. Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus. Arthritis Rheum. 2014;66 Suppl 10.
  • Scheinberg MA, Srinivasan D, Martin RS. The potential role of blisibimod for the treatment of systemic lupus erythematosus. International Journal of Clinical Rheumatology. 2014 9(2):121-134.
  • Golmia AP, Martin RS, Hislop C, Scheinberg MA. Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy. Rheumatology. 2013 Nov;53(5):957-8. doi:10.1093/rheumatology/ket361.
  • Furie RA, Thomas M, Chu A, Martin RS, Hislop C, Scheinberg MA. Effects of chronic treatment with blisibimod, an inhibitor of B cell activating factor, on renal and inflammation biomarkers in patients with systemic lupus erythematosus: observations from the placebo-controlled PEARL-SC and open-label extension studies. Arthritis Rheum. 2013;65 Suppl 10:1604.
  • Furie RA, Thomas M, Chu A, Martin RS, Hislop C, Scheinberg MA. Effects of blisibimod, an inhibitor of B cell activating factor, on serum immunoglobulins and infection risk in patients with systemic lupus erythematosus: observations from the placebo-controlled PEARL-SC and open-label extension studies. Arthritis Rheum. 2013;65 Suppl 10:1742.
  • Furie RA, Scheinberg MA, Leon G, Ramiterre EB, Thomas M, Chu AD, Hislop C, Martin RS, Petri MA. Effects of blisibimod, an inhibitor of B-cell activating factor, on markers of renal disease in patients with SLE. Ann Rheum Dis. 2013;72(Suppl3):95.
  • Scheinberg MA, Leon G, Abud-Mendoza C, Roimicher L, Hislop C, Martin RS, Petri M, Furie RA. Clinical experience in Latin America with blisibimod amongst subjects with active, moderate-to-severe systemic lupus erythematosus: Data from the Phase 2b PEARL-SC Study. 10th International Lupus Congress, Buenos Aires, Argentina, April 2013.
  • Hsu H, Khare SD, Lee F, Miner K, Hu YL, Stolina M, Hawkins N, Chen Q, Ho SY, Min H, Xiong F, Boone T, Zack DJ. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin Exp Rheumatol. 2012 Mar-Apr;30(2):197-201.
Print Friendly